DiaMedica Therapeutics Doses First Patients in Phase 2 Fetal Growth Restriction Trial
MT Newswires Live
Jun 23
DiaMedica Therapeutics (DMAC) said Tuesday it dosed the first two patients in a Phase 2 clinical trial evaluating its experimental drug DM199 for fetal growth restriction.
The study intends to evaluate three different dose levels of the treatment in a group of up to 30 participants, the company said.
The therapy is designed to improve blood flow through the maternal uterine artery to the placenta without entering the circulation of the fetus, DiaMedica said.
Shares of the company were up 3.2% in Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.